ROIV
insider transactionsRoivant Sciences Ltd. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-703.3K
0 buy · 703.3K sell
Net value · 90d
-$20.8M
$0 in · $20.8M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
4
0 buy · 703.3K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$0
200.0K sh
Own +5%
-
Sell·S
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$6.1M
200.0K sh · $30.27
Own -11%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$770.0K
200.0K sh · $3.85
Own +12%
-
Other·F
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$1.1M
34.5K sh · $32.41
Own -2%
-
Other·F
Richard Pulik KEY
CFO
$614.6K
19.0K sh · $32.41
Own -6%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$0
200.0K sh
Own +4%
-
Sell·S
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$5.9M
200.0K sh · $29.59
Own -11%
-
Exercise·M
Eric Venker KEY
President & Immunovant CEO · 10b5-1
$770.0K
200.0K sh · $3.85
Own +12%
-
Grant·A
Richard Pulik KEY
CFO
$0
84.0K sh
Own New
-
Grant·A
Richard Pulik KEY
CFO
$0
60.6K sh
Own +26%
-
Grant·A
Chief Accounting Officer
$0
27.2K sh
Own New
-
Grant·A
Chief Accounting Officer
$0
29.2K sh
Own +35%
-
Other·F
Director
$2.8K
95 sh · $29.83
Own -0%
-
Grant·A
Director
$0
896 sh
Own +1%
-
Other·F
Director
$2.8K
94 sh · $29.83
Own -0%
-
Grant·A
Director
$0
469 sh
Own +0%
-
Grant·A
Director
$0
670 sh
Own +4%
-
Sell·S
Matthew Gline KEY
CEO
$8.4M
289.8K sh · $29.16
Own -2%
-
Sell·S
Chief Accounting Officer
$384.1K
13.5K sh · $28.37
Own -14%
-
Other·F
Mayukh Sukhatme KEY
President & CIO
$5.2M
187.5K sh · $27.70
Own -1%
-
Other·F
Matthew Gline KEY
CEO
$8.4M
304.7K sh · $27.70
Own -2%
-
Other·F
Frank Torti KEY
President and Vant Chair
$4.4M
160.0K sh · $27.70
Own -1%
-
Exercise·M
Mayukh Sukhatme KEY
President & CIO
$15.0M
1.3M sh · $11.50
Own New
-
Other·F
Mayukh Sukhatme KEY
President & CIO
$787.3K
29.8K sh · $26.41
Own -0%
-
Exercise·M
Mayukh Sukhatme KEY
President & CIO
—
58.4K sh
Own +0%
-
Exercise·M
Matthew Gline KEY
CEO
$25.0M
2.2M sh · $11.50
Own New
-
Other·F
Matthew Gline KEY
CEO
$1.4M
53.8K sh · $26.41
Own -0%
-
Exercise·M
Matthew Gline KEY
CEO
—
97.3K sh
Own +1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 22, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $0 |
| May 22, 2026 | Eric Venker KEY 10b5-1 | Sell S | 200.0K | $6.1M |
| May 22, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $770.0K |
| May 20, 2026 | Eric Venker KEY 10b5-1 | Other F | 34.5K | $1.1M |
| May 20, 2026 | Richard Pulik KEY | Other F | 19.0K | $614.6K |
| Apr 20, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $0 |
| Apr 20, 2026 | Eric Venker KEY 10b5-1 | Sell S | 200.0K | $5.9M |
| Apr 20, 2026 | Eric Venker KEY 10b5-1 | Exercise M | 200.0K | $770.0K |
| Apr 20, 2026 | Richard Pulik KEY | Grant A | 84.0K | $0 |
| Apr 20, 2026 | Richard Pulik KEY | Grant A | 60.6K | $0 |
| Apr 20, 2026 | Jennifer Humes | Grant A | 27.2K | $0 |
| Apr 20, 2026 | Jennifer Humes | Grant A | 29.2K | $0 |
| Apr 17, 2026 | Ilan Oren | Other F | 95 | $2.8K |
| Apr 17, 2026 | Ilan Oren | Grant A | 896 | $0 |
| Apr 17, 2026 | James C Momtazee | Other F | 94 | $2.8K |
| Apr 17, 2026 | James C Momtazee | Grant A | 469 | $0 |
| Apr 17, 2026 | Melissa B, Epperly | Grant A | 670 | $0 |
| Apr 16, 2026 | Matthew Gline KEY | Sell S | 289.8K | $8.4M |
| Apr 8, 2026 | Jennifer Humes | Sell S | 13.5K | $384.1K |
| Mar 31, 2026 | Mayukh Sukhatme KEY | Other F | 187.5K | $5.2M |
| Mar 31, 2026 | Matthew Gline KEY | Other F | 304.7K | $8.4M |
| Mar 31, 2026 | Frank Torti KEY | Other F | 160.0K | $4.4M |
| Mar 30, 2026 | Mayukh Sukhatme KEY | Exercise M | 1.3M | $15.0M |
| Mar 30, 2026 | Mayukh Sukhatme KEY | Other F | 29.8K | $787.3K |
| Mar 30, 2026 | Mayukh Sukhatme KEY | Exercise M | 58.4K | — |
| Mar 30, 2026 | Matthew Gline KEY | Exercise M | 2.2M | $25.0M |
| Mar 30, 2026 | Matthew Gline KEY | Other F | 53.8K | $1.4M |
| Mar 30, 2026 | Matthew Gline KEY | Exercise M | 97.3K | — |
About ROIV insider trading
This page tracks insider transactions for Roivant Sciences Ltd. (ROIV) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.